Latest News

Updated results from Phase 3 trial of IVIG for Alzheimer's disease

Neurologists have reported new findings from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease. While the primary study outcomes were negative, observations from the subgroup analyses include whether there may be a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated Alzheimer's patients who have the ApoE4 genotype.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Baby cries show evidence of cocaine exposure during pregnancy

  • Bipolar disorder discovery at the nano level

  • Alternate approach to traditional CPR saves lives

  • Teenage self-harm linked to problems in later life

  • Unsteady on your feet? Little touches could make all the difference

  • Genes exhibit different behaviours in different stages of development

  • Susceptibility for relapsing major depressive disorder can be calculated

  • Clinical trial could change standard treatment for stroke

  • Criminologists try to solve murder mystery: Who will become a killer?

  • Association between air toxics, childhood autism

  •